Published in AIDS Weekly, May 26th, 1997
This is the largest trial of an HIV-specific immune-based therapy ever conducted in the U.S. and involves 2,500 HIV infected individuals at 74 medical centers around the United States. The trial is designed to determine the effectiveness of Remune in slowing the progression of HIV infection to AIDS or death. Remune is the first treatment of its kind to advance to a Phase III clinical trial.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.